Technology
Health
Biotechnology
Entasis Therapeutics
$6.349876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$6.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.09 (1.44%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ETTX and other stocks, options, ETFs, and crypto commission-free!
About
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. Read More The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.
Employees
33
Headquarters
Waltham, Massachusetts
Founded
2018
Market Cap
83.23M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
47.75K
High Today
$6.45
Low Today
$6.16
Open Price
$6.45
Volume
1.70K
52 Week High
$13.70
52 Week Low
$3.97
Collections
Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Pharmaceutical
2018 IPO
News
NasdaqApr 30
Entasis Therapeutics to Participate in the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will host one-on-one meetings with investors at the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit being held May 7-9, 2019 in New York, New York. Investors attending t...
Price Paid on Robinhood
22% Lower
Right Now
52 Week Low
$3.97
Average Price Paid
$8.16
52 Week High
$13.70
Earnings
-$20.00
-$13.60
-$7.20
-$0.80
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.80 per share
Actual
-$0.99 per share